Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

New consensus recommendations address implementation of novel treatments and imaging techniques for advanced and ...

The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with ...

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...

Survey results add to evidence showing that more than half of US patients with mCSPC are still receiving androgen deprivation therapy (ADT) alone or ADT with a nonsteroidal antiandrogen. Despite ...

Although treatments like androgen deprivation therapy have been effective for early-stage prostate cancer, advanced stages, such as castration-resistant prostate cancer, present significant ...

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...